Diffusion Pharmaceuticals
Charlottesville
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion’s product candidate DFN-529, a novel PI3K/Akt/mTOR pathway inhibitor, is in early-stage development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $119.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:DFFN
- Website: diffusionpharma.com
- Phone: +1 434 220 0722
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/diffusion-pharmaceuticals-199326 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.